Vasodilators Global Market 2024 - Growth Opportunities, Top Countries, Future Trends, Revenue And Forecast 2033

The Business Research Company recently released a comprehensive report on the Global Vasodilators Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16565&type=smp

According to The Business Research Company's, The vasodilators market size has grown strongly in recent years. It will grow from $6.01 billion in 2023 to $6.40 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased awareness and diagnosis, government initiatives and healthcare policies, rising health awareness among the people, advancements in gene therapy, and increasing adoption of artificial intelligence.

The vasodilators market size is expected to see strong growth in the next few years. It will grow to $8.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to the rising prevalence of hypertension and cardiovascular diseases, growing demand for advanced medical technology for cardiac diseases, the increasing geriatric population worldwide, the rising prevalence of diabetes and high blood pressure, growing importance of personalized medicine. Major trends in the forecast period include strategic mergers and acquisitions, the shift towards outpatient settings and home-based care, product innovations, technological advancements, and expansion of healthcare infrastructure.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Market Drivers and Trends:

The rising prevalence of cardiovascular diseases is expected to propel the growth of the vasodilators market going forward. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke, often linked to hypertension and other risk factors. The increasing prevalence of cardiovascular diseases is primarily driven by sedentary lifestyles, poor dietary habits, obesity, tobacco use, and aging populations. Vasodilators are used in cardiovascular diseases to relax blood vessels, reduce blood pressure, and improve blood flow. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based public agency, coronary artery disease (CAD) was responsible for killing 375,476 people in 2021, and about 1 in 20 adults age 20 and older had CAD. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of the vasodilators market.

Sedentary Lifestyles Fuel Growth In The Vasodilator Market

The increased adoption of sedentary lifestyles is expected to propel the growth of the vasodilators market going forward. A sedentary lifestyle refers to limited physical activity and excessive time spent sitting or lying down, often associated with minimal exercise or movement. It is increasing due to modern conveniences such as technology, transportation, and desk-bound jobs, which promote prolonged periods of inactivity. The increased adoption of sedentary lifestyles is driven by technological advancements and modern work environments that prioritize convenience and prolonged sitting. In sedentary lifestyles, vasodilators can improve blood flow and reduce hypertension, mitigating cardiovascular risks. For instance, in September 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, new population data from 2022 indicate that 22 states have an adult obesity rate of 35% or higher, up from 19 states in 2021. Therefore, the increased adoption of sedentary lifestyles is driving the growth of the vasodilators market.

Major companies operating in the vasodilators market are focusing on developing advanced products, such as soluble guanylate cyclase (sGC) stimulators, to gain a competitive edge in the market. Soluble guanylate cyclase (sGC) refers to an enzyme found in cells, particularly in smooth muscle cells lining blood vessels. When activated, soluble guanylate cyclase (sGC) converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), leading to vasodilation and increased blood flow. For instance, in September 2022, Bayer AG, a Germany-based pharmaceutical and biotechnology company, launched Vericiguat (Verquvo), a soluble guanylate cyclase (sGC) stimulator for adults with symptomatic chronic heart failure. The drug targets a pathway not currently targeted by existing treatments, reducing the risk of cardiovascular death and hospitalization.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc., Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., AstraZeneca, Mayo Foundation for Medical Education and Research (MFMER), Boehringer Ingelheim International GmbH, Bayer AG, Viatris Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen

Vasodilators Market 2024 Key Insights:

• The vasodilators market size is expected to see strong growth in the next few years. It will grow to $8.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%.
• Rising Cardiovascular Diseases Propel Vasodilator Market Growth
• Advancements In Soluble Guanylate Cyclase (sGC) Stimulators
• North America was the largest region in the vasodilators market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=16565&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.